The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The expansion includes a larger technical and service team and increased local procurement
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The update promises to revolutionize laboratory workflows by optimizing resources
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The new facility is expected to generate 500-600 new jobs in the region
The state-of-the-art facility is expected to be commissioned over the next three years
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Subscribe To Our Newsletter & Stay Updated
